Physicians' Academy for Cardiovascular Education

Comparable cardiovascular risk reduction with PCSK9 antibodies and statins

Reduction of low density lipoprotein-cholesterol and cardiovascular events with proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors and statins: an analysis of FOURIER, SPIRE, and the Cholesterol Treatment Trialists Collaboration

Literature - Ference BA, Cannon CP, Landmesser U, et al. - European Heart Journal 2107; published online ahead of print

Main results


PCSK9 antibodies and statins comparably reduce the risk of CV events and slightly increase risk of DM, proportional to the absolute achieved reduction in LDL-C and the total duration of therapy. These data support the focus on LDL-C targets in the prevention of cardiovascular disease.


Show references

Find this article online at European Heart Journal

Share this page with your colleagues and friends: